Valerie Gouon-Evans, PharmD, PhD is Associate Professor of Medicine in the Section of Gastroenterology at the Chobanian and Avedisian School of Medicine, Director of the Program of Boston University Liver Biologists (BULB), and Associate Director of the Molecular & Translational Medicine (MTM) PhD Program of the Department of Medicine.
After completing her graduate studies in Paris, Dr. Gouon-Evans joined Dr. Pollard's Lab as a postdoctoral fellow where she studied mammary gland development and breast cancer. She then began her career as an Instructor of Gene and Cell Medicine at the Icahn School of Medicine at Mount Sinai School of Medicine in New York in the laboratory of Dr. Gordon Keller, where she pioneered protocols to efficiently generate hepatocyte-like cells from pluripotent stem cells. She quickly rose up the ranks and was promoted to Assistant Professor before arriving at Boston University. As a PharmD PhD lab leader for 16 years, Dr. Gouon-Evans has overseen the creation of a research program to advance understanding of liver development and establishing therapeutic strategies to alleviate liver disease using an induced pluripotent stem cell platform and mouse models. Recently, Dr. Gouon-Evans lab also pioneered an innovative technology to deliver regenerative factors to the liver to treat various liver diseases, by using mRNA complexed to lipid nanoparticles, which is a validated platform with the widely used mRNA-based COVID-19 vaccines.
Diversity, Equity, Inclusion and Accessibility
I am a strong believer in the power of diversity for advancing science. Developing daily awareness to equity, inclusion and belonging is critical to empower diversity, and is therefore a continuous societal endeavor I advocate and commit to in my lab, work environment and life in general. My willingness and dedication to increase this awareness and to implement actions toward diversity have been fed by two instrumental leadership training programs on the BU campus, the Woman Leadership program, and the Mid-career Faculty Leadership (MFL) program. Especially, the MFL program gave me the incredible opportunity to be part of a leader group who established a proposal for the program “Report. Respond. Restore” addressing interpersonal mistreatments at Boston University Chobanian and Avedisian School of Medicine, a program that if implemented would certainly help create a safer work environment where everybody can thrive.
Below are some specific examples of my Diversity, Equity, Inclusion, and Belonging activities. I mentor BU PREP students and train them for their coming PhD program applications through mock interviews. I mentor underrepresented undergraduate students and guide them in their future career path. As the co-director of the Molecular & Translational Medicine PhD program, I support recruitment of URG PhD students with financial compensation through the program. My lab has been an active participant in the anti-racism activities organized by the CReM and notably presented at the CReM anti-racism journal club series. As the first woman PI hired at the CReM, I take pride to continuously promote women in science especially women from diverse backgrounds from undergraduate to graduate levels. Overall, I believe that harnessing Diversity, Equity, Inclusion, and Belonging is a must for advancing science in a healthy environment where all thrive. Yet, I recognize that this is a societal work in progress, and I have the willpower and dedication to continue to implement my DEI effort in my daily life.
Center for Regenerative Medicine
Evans Center for Interdisciplinary Biomedical Research
Genome Science Institute
Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
Primary hepatocyte and engineered iPSC-derived hepatocyte-like cell transplantation to treat alpha-1 antitrypsin deficiencyassociated liver disease
02/01/2023 - 01/31/2026 (Key Person / Mentor)NIH/National Diabetes & Digestive & Kidney Diseases1F31DK135378-01
Sexual dimorphism of acetaminophen-induced liver injury and regeneration
07/01/2021 - 10/31/2022 (Key Person / Mentor)NIH/National Diabetes & Digestive & Kidney Diseases5F31DK127606-02
Investigation of the role of VEGFA in harnessing cholangiocyte-driven liver regeneration
07/01/2022 - 04/30/2027 (PI)National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS5R01DK133404-02
A multi-modular approach for human pluripotent stem cell-based liver regeneration
09/15/2020 - 07/31/2024 (PI)National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS1R01DK124361-01A1
Engineered and edited patient-derived iPSC for AATD-associated liver disease cell therapy
07/01/2022 - 06/30/2024 (PI)Alpha-1 Foundation
Edited stem cell-based therapy with transcript therapy for AATD-associated liver disease
07/01/2019 - 06/30/2022 (PI)Alpha-1 Foundation
Use of Human Pluripotent Stem Cell-derived Hepatic Cells in Pediatric Liver Transplantation
07/01/2017 - 05/31/2018 (PI)March of Dimes
Showing 10 of 16 results.
Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 37 results.
Everton E, Del Rio-Moreno M, Villacorta-Martin C, Singh Bawa P, Lindstrom-Vautrin J, Muramatsu H, Rizvi F, Smith AR, Tam Y, Pardi N, Kineman R, Waxman DJ, Gouon-Evans V. Growth Hormone Accelerates Recovery From Acetaminophen-Induced Murine Liver Injury. bioRxiv. 2023 Apr 18.View Related Profiles. PMID: 37131727; PMCID: PMC10153200; DOI: 10.1101/2023.04.17.537197;
Rizvi F, Lee YR, Diaz-Aragon R, So J, Florentino RM, Smith AR, Everton E, Ostrowska A, Jung K, Tam Y, Muramatsu H, Pardi N, Weissman D, Soto-Gutierrez A, Shin D, Gouon-Evans V. VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis. bioRxiv. 2023 Apr 18. PMID: 37131823; PMCID: PMC10153196; DOI: 10.1101/2023.04.17.537186;
Gouon-Evans V, Fiorotto R. Fibroblasts to hepatocytes: A nonstop flight into cell therapy for liver diseases? Hepatology. 2023 May 01; 77(5):1469-1471. PMID: 35957526
Smith AR, Gouon-Evans V. c-Maf: The magic wand that turns on LSEC fate. Cell Stem Cell. 2022 Apr 07; 29(4):491-493. PMID: 35395181
Everton E, Rizvi F, Smith AR, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V. Transient yet Robust Expression of Proteins in the Mouse Liver via Intravenous Injection of Lipid Nanoparticle-encapsulated Nucleoside-modified mRNA. Bio Protoc. 2021 Oct 05; 11(19):e4184.View Related Profiles. PMID: 34722830; PMCID: PMC8517647; DOI: 10.21769/BioProtoc.4184;
Rizvi F, Everton E, Smith AR, Liu H, Osota E, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V. Author Correction: Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun. 2021 May 10; 12(1):2825.View Related Profiles. PMID: 33972545; PMCID: PMC8110992; DOI: 10.1038/s41467-021-23322-6;
Rizvi F, Everton E, Smith AR, Liu H, Osota E, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun. 2021 01 27; 12(1):613.View Related Profiles. PMID: 33504774; PMCID: PMC7840919; DOI: 10.1038/s41467-021-20903-3;
Han S, Tan C, Ding J, Wang J, Ma'ayan A, Gouon-Evans V. Endothelial cells instruct liver specification of embryonic stem cell-derived endoderm through endothelial VEGFR2 signaling and endoderm epigenetic modifications. Stem Cell Res. 2018 07; 30:163-170. PMID: 29936335; DOI: 10.1016/j.scr.2018.06.004;
Bardot E, Calderon D, Santoriello F, Han S, Cheung K, Jadhav B, Burtscher I, Artap S, Jain R, Epstein J, Lickert H, Gouon-Evans V, Sharp AJ, Dubois NC. Foxa2 identifies a cardiac progenitor population with ventricular differentiation potential. Nat Commun. 2017 02 14; 8:14428. PMID: 28195173; PMCID: PMC5316866; DOI: 10.1038/ncomms14428;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
2010 Federation of American Societies for Experimental Biology (FASEB):
2008 Federation of American Societies for Experimental Biology (FASEB):
2007-2008 International Society for Stem Cell Research: